Innoviva Market Cap 2010-2025 | INVA

Innoviva market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of May 08, 2025 is $1.16B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.165B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $712.176B 54.61
Johnson & Johnson (JNJ) United States $374.529B 15.49
AbbVie (ABBV) United States $328.287B 18.07
Novo Nordisk (NVO) Denmark $291.016B 19.19
Roche Holding AG (RHHBY) Switzerland $249.441B 0.00
Novartis AG (NVS) Switzerland $232.641B 13.28
Merck (MRK) United States $194.982B 9.97
Sanofi (SNY) France $131.694B 12.59
Pfizer (PFE) United States $130.593B 7.16
Bayer (BAYRY) Germany $26.093B 4.85